Breast cancer drug halves relapse rate.

Breast cancer drug halves relapse rate.:

"International clinical trials of 5,000 women found that Herceptin cut the chances of relapse in women suffering from the aggressive form of breast cancer known as HER2-positive."

The American studies of the drug Herceptin, which were reported in the New England Journal of Medicineare more good news because this particular drug can extend the life of women suffering from
the aggressive form of HER2-positive. The drug can affect the heart but if you read the article, it's a risk run by some women who have chemo therapy and they are able to reverse the problems for some of the women. In any case, more women will stay alive because of this. The chief executive of the Australian Cancer Council, Professor Alan Coates, wants this drug made available on the pharmaceutical benefits lists so women can access it. As I said, we need to keep the break throughs coming one at a time.